Genedrive PLC (LSE:GDR) - Share price


Stock Report

Genedrive PLC GDR

Last Price
GBX39.60

Day Change
8.60|27.74%

As of 02/12/2021
16:40:18 GMT | GBX
Minimum 15 Minutes Delay.

Last Close31.00p
Day Range31.00 - 41.90
Mkt Cap28.45Mil
52-Wk Range15.75 - 165.00
Yield %-
ISINGB00B1VKB244
Volume24,152,270
P/E-
P/S0.34
P/CF-0.05

Share Price

Total Returns 01/12/2021

 Chg (%)  
More ...
Genedrive PLC41.71 
FTSE 100 TR GBP-1.35
 
Financials
201920202021
More ...
Income Statement
Turnover0.961.060.69
Operating Profit-4.45-5.64-5.48
Net Profit-3.64-19.42-0.69
Reported EPS-14.00-55.00-1.20
Balance Sheet
Current Assets6.9410.264.53
Non Current Assets0.320.190.35
Total Assets7.2610.454.88
Current Liabilities1.222.201.29
Total Liabilities9.7413.801.29
Total Equity-2.48-3.343.59
Cash Flow
Operating Cash Flow-4.60-4.76-6.17
Net Change in Cash1.673.03-5.61

Regulatory News

DateAuthor Headline
14/07/2014Emma Wall Woodford's Full Portfolio Revealed
Woodford is maximising his overseas exposure and allocating a third of the portfolio to his favourite sector, pharmaceuticals, as well as a surprisingly high financials exposure
03/07/2013Cherry Reynard Should Commercial Property Be Back on Your Buy List?
The toxic combination of a weakening economy and the legacy of a spectacular boom and bust has left commercial property off most investors' buy lists
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
01/10/2021PurchaseDr. Ian David Gilham25.00111,12127,780.00
01/10/2021PurchaseMr. Chris Henry Francis Yates25.0020,0005,000.00
01/10/2021PurchaseMr. David Budd25.0080,00020,000.00
01/10/2021PurchaseMr. Matthew John Fowler25.0040,00010,000.00

Company Profile

Genedrive PLC is a holding company engaged in molecular diagnostics business. It operates in one operating segment named as Diagnostics which is engaged in Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Geographically the majority of the revenue is derived from the United States of America.

Sector

Diagnostics & Research

Index

FTSE AIM All-Share

Next Event 30/12/2021

Annual General Meeting
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-45.02
Op Mrgn-7.98
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, ChairmanDr. Ian David Gilham
Non-Executive DirectorMr. Chris Henry Francis Yates
Executive Director, Chief Executive OfficerMr. David Budd
Executive Director, Chief Financial Officer and Company SecretaryMr. Matthew John Fowler
Non-Executive DirectorMr. Thomas Lindsay
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.